Table 4.
Persistent organic pollutants (POPs) and odds of fibroid diagnosis in sensitivity analysis excluding women with postoperative diagnosis of endometriosis, ENDO Study, 2005–2009 (n=283).
| Fibroids only (n=63) vs. no fibroids no endo (n=220) | ||
|---|---|---|
| Omental fat Adjusted OR (95% CI)* |
Serum Adjusted OR (95% CI)* |
|
| Analyte | ||
| HCB | 0.86 (0.51, 1.44) | 0.74 (0.51, 1.07) |
| γ-HCH | 0.55 (0.27, 1.09) | 0.98 (0.70, 1.38) |
| β-HCH | 0.79 (0.51, 1.20) | 1.01 (0.74, 1.39) |
| p,p′-DDT | 1.11 (0.72, 1.71) | 1.13 (0.79, 1.61) |
| o,p′-DDE | 0.67 (0.42, 1.07) | 1.01 (0.66, 1.55) |
| p,p′-DDE | 1.19 (0.74, 1.91) | 1.24 (0.87, 1.77) |
| CHLORDANES | ||
| trans-chlordane | 0.86 (0.52, 1.42) | 0.78 (0.41, 1.47) |
| cis-chlordane | 1.08 (0.73, 1.60) | 0.75 (0.40, 1.41) |
| cis-nonachlor | 0.95 (0.56, 1.61) | 1.08 (0.74, 1.55) |
| trans-nonachlor | 1.53 (0.91, 2.58) | 1.06 (0.73, 1.53) |
| oxychlordane | 1.61 (0.91, 2.84) | 1.01 (0.59, 1.73) |
| PBDEs | ||
| PBDE 47 | 1.08 (0.73, 1.61) | 1.18 (0.82, 1.70) |
| PBDE 99 | 1.09 (0.74, 1.60) | 1.30 (0.85, 1.99) |
| PBDE 100 | 1.07 (0.70, 1.62) | 0.97 (0.64, 1.46) |
| PBDE 153 | 1.06 (0.71, 1.58) | 0.87 (0.56, 1.35) |
| PBDE 154 | 1.11 (0.83, 1.47) | 1.32 (0.88, 1.96) |
| PBDE 183 | 0.58 (0.27, 1.23) | 0.81 (0.54, 1.22) |
| PBDE 209 | 0.93 (0.62, 1.40) | 1.17 (0.84, 1.63) |
| PCBs | ||
| PCB 18 | 1.30 (0.90, 1.88) | 0.90 (0.61, 1.33) |
| PCB 28 | 0.80 (0.45, 1.43) | 1.00 (0.67, 1.51) |
| PCB 44 | 0.93 (0.41, 2.12) | 0.63 (0.35, 1.11) |
| PCB 49 | 0.74 (0.37, 1.51) | 0.67 (0.34, 1.35) |
| PCB 52 | 0.78 (0.42, 1.45) | 0.66 (0.40, 1.09) |
| PCB 66 | 1.08 (0.82, 1.41) | 0.62 (0.38, 1.01) |
| PCB 74 | 1.33 (0.87, 2.06) | 0.59 (0.33, 1.06) |
| PCB 87 | 0.97 (0.65, 1.45) | 0.73 (0.46, 1.15) |
| PCB 99 | 1.64 (1.08, 2.49) | 0.62 (0.32, 1.19) |
| PCB 101 | 1.00 (0.56, 1.76) | 0.75 (0.48, 1.17) |
| PCB 118 | 1.27 (0.86, 1.88) | 0.71 (0.39, 1.29) |
| PCB 128 | 0.72 (0.41, 1.26) | 0.84 (0.41, 1.72) |
| PCB 138 | 1.64 (1.03, 2.59) | 0.76 (0.47, 1.22) |
| PCB 146 | 1.54 (1.01, 2.37) | 0.83 (0.49, 1.41) |
| PCB 149 | 0.89 (0.52, 1.52) | 0.83 (0.53, 1.31) |
| PCB 151 | 0.90 (0.50, 1.61) | 0.84 (0.56, 1.28) |
| PCB 153 | 1.88 (1.12, 3.13) | 0.76 (0.48, 1.21) |
| PCB 156 | 1.37 (0.96, 1.96) | 0.85 (0.56, 1.28) |
| PCB 157 | 0.80 (0.47, 1.36) | 0.85 (0.56, 1.28) |
| PCB 167 | 1.12 (0.76, 1.66) | 1.05 (0.73, 1.51) |
| PCB 170 | 1.34 (0.86, 2.11) | 0.94 (0.67, 1.31) |
| PCB 172 | 1.06 (0.72, 1.57) | 1.05 (0.78, 1.40) |
| PCB 177 | 1.32 (0.87, 1.98) | 0.65 (0.41, 1.05) |
| PCB 178 | 1.25 (0.84, 1.86) | 0.89 (0.60, 1.31) |
| PCB 180 | 1.46 (0.90, 2.39) | 0.79 (0.54, 1.16) |
| PCB 183 | 1.40 (0.91, 2.16) | 0.95 (0.67, 1.35) |
| PCB 187 | 1.31 (0.82, 2.10) | 0.84 (0.58, 1.21) |
| PCB 189 | 0.72 (0.42, 1.23) | 0.94 (0.67, 1.32) |
| PCB 194 | 1.32 (0.84, 2.09) | 0.28 (0.02, 3.62) |
| PCB 195 | 1.01 (0.66, 1.55) | 1.71 (0.64, 4.54) |
| PCB 196 | 1.60 (1.02, 2.51) | 0.66 (0.27, 1.60) |
| PCB 201 | 1.02 (0.68, 1.52) | 0.61 (0.25, 1.49) |
| PCB 206 | 1.52 (1.01, 2.29) | 1.32 (0.92, 1.90) |
| PCB 209 | 1.17 (0.75, 1.81) | 0.94 (0.50, 1.77) |
| PFCs | ||
| PFOS | 0.88 (0.62, 1.24) | |
| PFOA | 0.72 (0.50, 1.03) | |
| PFNA | 0.74 (0.50, 1.08) | |
| PFDA | 0.62 (0.39, 0.99) | |
| PFHxS | 0.96 (0.65, 1.44) | |
| PFHpA | 0.93 (0.64, 1.35) | |
| PFUNDA | 1.28 (0.89, 1.84) | |
| PFDoDA | 0.96 (0.62, 1.49) | |
| PFOSA | 1.29 (0.90, 1.85) | |
All chemical concentrations were log(x+1) transformed then rescaled by the standard deviation (SD) for analysis; results are odds of a fibroids diagnosis per one SD change in POP concentration.
*
Odds ratios (OR) adjusted for age (continuous), race (black vs. others), BMI (categorical at <29.9 vs. >=30.0), smoking status (based on cotinine cutoffs of current vs. non-smoker), site, and lipid (total fat lipid or serum lipids**).
**
Serum lipid = (serum total cholesterol × 2.27) + serum triglycerides + 62.3.